Mechanism of Action of Ivabradine
Ivabradine selectively blocks the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker If ("funny") current in the sinoatrial node, resulting in heart rate reduction without affecting ventricular repolarization or myocardial contractility. 1
Primary Cardiac Effects
Ivabradine works by:
- Selectively inhibiting the If current in sinoatrial (SA) node pacemaker cells, which regulates the spontaneous diastolic depolarization phase (phase 4) of the action potential 1
- Reducing heart rate in a dose-dependent manner without negative inotropic effects (no reduction in contractility) 1
- Producing approximately 10 bpm reduction in heart rate at rest and during exercise at recommended doses 1
The cardiac effects are most pronounced at the SA node, though prolongation of the AH interval and PR interval can occur 1. Importantly, ivabradine does not affect ventricular repolarization and causes no rate-corrected QT prolongation 1.
Use-Dependent Blocking Properties
A critical feature distinguishing ivabradine from beta-blockers is its use-dependent mechanism: the drug accumulates during repetitive channel activation/deactivation cycles, meaning it has a more substantial blocking effect at higher heart rates 2. This makes it particularly effective for tachycardic conditions, as the drug works more efficiently when the heart rate is elevated.
Non-Cardiac Effects
Ivabradine also inhibits the retinal current Ih, which is involved in curtailing retinal responses to bright light stimuli. This can cause luminous phenomena (phosphenes)—transient enhanced brightness in limited areas of the visual field, particularly with rapid changes in luminosity 1.
Clinical Context
According to the 2022 AHA/ACC/HFSA guidelines, ivabradine functions as a sinoatrial node modulator and is indicated for patients with symptomatic HFrEF (LVEF ≤35%) who are in sinus rhythm with heart rate ≥70 bpm despite maximally tolerated beta-blocker therapy 3, 4. The benefit derives specifically from heart rate reduction, with greater effects observed in patients with higher baseline heart rates 1.